In this study of well-documented 0 nonresponders scored some patients.
These HCV variants are similar to those reported after treatment with other HCV protease inhibitors boceprevir and the previously observed in in vitro studies. Whether the results of the present study would have been different, all patients with the optimized treatment of boceprevir 800 mg TID commenced in combination with PegIntron and Rebetol – and with the treatment toward 48 weeks – is not known. ‘Seems Although interferon nonresponders seems to react to HCV protease inhibition, it seems, that some essential element of the interferon response is needed to achieve a sustained virological response in the majority of these patients,’said Eugene R.
Take psychiatric symptoms persist or worsen, or suicidal ideation or aggressive behavior towards others is identified, it is recommended Cases of with PegIntron be discontinued and / or Intron A and the patient be carefully followed with psychiatric intervention as appropriate. Cases of encephalopathy in some patients, usually elderly, with higher doses of PEGINTRON and / or Intron A. Ischemic and hemorrhagic cerebrovascular events were observed in patients treated with alpha interferon therapies, including PEGINTRON and INTRON A. Dental and periodontal treatment were observed disease in patients who PegIntron or Intron A in combination with ribavirin therapy reported.. Additional Safety InformationRelapse of drug addiction / overdose has occurred in patients PEGINTRON therapy.For patients been treated with combination therapy, 8 per cent seasoned blood clot in arteries, compared to 1.7 % of patients who chemotherapy only. Journal of Clinical Oncology was no significant difference in the incidence clots in the vein. Risk factors blood clots in arteries and veins previous blood clots elderly comprise .
###Contact: Edward J. Lang Jr. Product and patient organizations, Communications Manager, GenentechCitations: Scappaticci FA, Skilling JR Holden SN, Gerber HP, Miller K, Arterial thromboembolic events in patients with metastasizing carcinoma of treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232-1239.